Guido Marcucci
City of Hope Medical Center · James Cancer Hospital · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Guido Marcucci as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04655391 · Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationCity of Hope Medical Center · withdrawn · Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1NCT03009240 · Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaCity of Hope Medical Center · completed · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- N/ANCT01463410 · Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfilerSkyline Diagnostics BV · terminated · Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Refractory Anemia With Excess of Blasts (RAEB) · principal investigator
- Ph2NCT01238211 · Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNational Cancer Institute (NCI) · completed · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · principal investigator
- N/ANCT00898092 · Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology · unknown · Leukemia · study chair
- Ph1NCT00624936 · Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesOhio State University Comprehensive Cancer Center · completed · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms · principal investigator
- Ph3NCT00085124 · Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid LeukemiaNational Cancer Institute (NCI) · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · principal investigator
- Ph1NCT00004862 · Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI) · completed · Leukemia · study chair
- Ph1NCT00070551 · GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaNational Cancer Institute (NCI) · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · principal investigator
- Ph1NCT00024180 · FR901228 in Treating Patients With Hematologic CancerOhio State University Comprehensive Cancer Center · completed · Leukemia, Lymphoma · study chair
- Ph1NCT00039117 · Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapyU01CA293853 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $590,960 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Immune Escape in CML/MPN TransformationR01CA286160 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $571,615 awarded in 2026Same name and institution; not confirmed by an ID
- The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AMLR01CA258981 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2022 to 2026 · $542,890 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting MicroRNAs to Eradicate Leukemia Stem CellsR01CA205247 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2017 to 2025 · $1,011,514 awarded in 2025Same name and institution; not confirmed by an ID
- Information flow and state transitions at the system and multi-dimensional scales in leukemia progressionU01CA250046 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2020 to 2024 · $623,198 awarded in 2024Same name and institution; not confirmed by an ID
- Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?R01CA248475 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2020 to 2024 · $485,048 awarded in 2024Same name and institution; not confirmed by an ID
- Biologic and Therapeutic Significance of miR-155 in AMLR01CA201184 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2016 to 2020 · $528,129 awarded in 2020Same name and institution; not confirmed by an ID
- ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · fiscal years 2014 to 2018 · $684,551 awarded in 2018Same name and institution; not confirmed by an ID
- Pharmacological modulation of epigenetic changes in AMLR01CA102031 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2004 to 2017 · $342,107 awarded in 2017Same name and institution; not confirmed by an ID
- Targeting the aberrant kinome-epigenome in AMLR01CA158350 · NCI · OHIO STATE UNIVERSITY · fiscal years 2012 to 2016 · $308,958 awarded in 2016Same name and institution; not confirmed by an ID
- Leukemia Tissue BankP30CA016058 · NCI · OHIO STATE UNIVERSITY · fiscal years 2012 to 2015 · $44,226 awarded in 2015Same name and institution; not confirmed by an ID
- Validation of microRNAs as therapeutic targets in hematological malignanciesR01CA135332 · NCI · OHIO STATE UNIVERSITY · fiscal years 2011 to 2015 · $316,438 awarded in 2015Same name and institution; not confirmed by an ID
- Cancer and Leukemia Group B - Leukemia Correlative SciencesU10CA101140 · NCI · OHIO STATE UNIVERSITY · fiscal years 2010 to 2013 · $742,430 awarded in 2013Same name and institution; not confirmed by an ID
- SPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · fiscal years 2009 to 2013 · $107,207 awarded in 2013Same name and institution; not confirmed by an ID
- GTI-2040: An anti-sense strategy to reduce ribonucleotide reductase in AMLR21CA133879 · NCI · OHIO STATE UNIVERSITY · fiscal years 2009 to 2010 · $335,500 awarded in 2010Same name and institution; not confirmed by an ID
- Molecular characterization of normal cytogenetics AML in older patientsR21CA129657 · NCI · OHIO STATE UNIVERSITY · fiscal years 2008 to 2009 · $168,750 awarded in 2009Same name and institution; not confirmed by an ID
- LARG, A Novel Leukemia Associated Guanine Exhange FactorK08CA090469 · NCI · OHIO STATE UNIVERSITY · fiscal years 2001 to 2006 · $55,215 awarded in 2006Same name and institution; not confirmed by an ID
- Pharmacologic modulation of chromatin remodeling in leu*R21CA115019 · NCI · OHIO STATE UNIVERSITY · fiscal years 2005 to 2006 · $259,492 awarded in 2006Same name and institution; not confirmed by an ID
- A PHASE I STUDY OF DECITABINE IN COMBINATION WITH VALPROIC ACIDM01RR000034 · NCRR · OHIO STATE UNIVERSITY · fiscal years 2005 · $8,754 awarded in 2005Same name and institution; not confirmed by an ID
- Ribonucleotide Reductase Antisense Strategy in AMLR21CA105879 · NCI · OHIO STATE UNIVERSITY · fiscal years 2003 to 2004 · $319,788 awarded in 2004Same name and institution; not confirmed by an ID
- BCI2 Antisense Against Chemoresistance in Elderly AMLR21CA094552 · NCI · OHIO STATE UNIVERSITY · fiscal years 2002 to 2003 · $331,875 awarded in 2003Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2011 to 2026Named on NCT04655391, NCT03009240
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT01238211, NCT00898092
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 2011 to 2013
- Phase I Trials of Anti-Cancer AgentsU01CA076576 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL R GREVER · fiscal years 2011 to 2013Named on NCT00070551, NCT00039117
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:33 UTC. The ranking covers the 200 most relevant of 59 PubMed records, and a shared surname and initials can bring in a namesake. All 59 on PubMed
- 1,934 citationsRCR 65.6
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.Proc Natl Acad Sci U S A · 2010394 citationsRCR 8.9
- 350 citationsRCR 6.9
- 344 citationsRCR 6.4
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.J Clin Oncol · 2011272 citationsRCR 5.9
- Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.J Clin Oncol · 2007258 citationsRCR 5.3
- 230 citationsRCR 5.5
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.J Clin Oncol · 2024220 citationsRCR 34.4
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Proc Natl Acad Sci U S A · 2014205 citationsRCR 5.5
- 182 citationsRCR 3.4